<SEC-DOCUMENT>0001193125-16-654375.txt : 20160722
<SEC-HEADER>0001193125-16-654375.hdr.sgml : 20160722
<ACCEPTANCE-DATETIME>20160722075956
ACCESSION NUMBER:		0001193125-16-654375
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160722
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160722
DATE AS OF CHANGE:		20160722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOTEK PHARMACEUTICALS CORP
		CENTRAL INDEX KEY:			0001281895
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36829
		FILM NUMBER:		161778514

	BUSINESS ADDRESS:	
		STREET 1:		91 HARTWELL AVE
		STREET 2:		2ND FLOOR
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-676-2100

	MAIL ADDRESS:	
		STREET 1:		91 HARTWELL AVE
		STREET 2:		2ND FLOOR
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d231137d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): July&nbsp;22, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Inotek Pharmaceuticals Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>001-36829</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>04-3475813</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of <BR>incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>91 Hartwell Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lexington, MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>02421</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Registrant&#146;s telephone number, including area code <B>(781)&nbsp;676-2100 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P><center> <P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;22, 2016, Inotek Pharmaceuticals Corporation (the &#147;Company&#148;)
issued a press release announcing that the United States Patent and Trademark Office issued a composition of matter patent for the combination of the Company&#146;s lead product candidate, <I>trabodenoson</I>, with a prostaglandin analog for the
treatment of intraocular pressure in patients with glaucoma. A copy of the press release is filed as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item&nbsp;8.01. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d) Exhibits. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated July&nbsp;22, 2016</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: July&nbsp;22, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INOTEK PHARMACEUTICALS CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dale Ritter</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dale Ritter</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President&#151;Finance</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated July&nbsp;22, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d231137dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g231137g04d36.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Inotek Pharmaceuticals Expands Intellectual Property Portfolio with Combination Patent </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Covers Combination of Trabodenoson and</I> a <I>Prostaglandin for Reducing Intraocular Pressure in Glaucoma - </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LEXINGTON, Mass</B> &#150; July&nbsp;22, 2016 &#150; Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused
on the discovery, development and commercialization of therapies for glaucoma and other eye diseases, today announced that the United States Patent and Trademark Office issued a composition of matter patent for the combination of the Company&#146;s
lead product candidate, <I>trabodenoson,</I> with a prostaglandin analog for the treatment of intraocular pressure (IOP) in patients with glaucoma. US Patent number 9,370,530 (&#146;530 patent) further strengthens the Company&#146;s patent estate
for <I>trabodenoson</I> and adds composition of matter intellectual property protection for the combination or kit treatment option until 2031. <I>Trabodenoson</I>, the Company&#146;s lead clinical product candidate, is a first-in-class, selective
adenosine mimetic targeting the A<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>&nbsp;receptor and has been observed in Phase 2 clinical trials to reduce IOP, an important risk factor for glaucoma. Prostaglandin analogs are currently the
most commonly used drug class for this disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Earlier this month, Inotek announced the initiation of their Phase 2 dose-ranging trial of a fixed-dose
combination (FDC) of <I>trabodenoson</I> and <I>latanoprost</I>, the most commonly used prostaglandin analog prescribed for glaucoma. Glaucoma is one of the leading causes of blindness, and occurs when there is damage to the optic nerve, often as a
result of elevated eye pressure. While the goal of glaucoma treatment is to preserve vision, lowering IOP has been shown to prevent progressive vision loss. There are currently no FDC products for glaucoma treatment that include a prostaglandin
analog that are approved in the United States, even though about half of glaucoma patients that start treatment with a prostaglandin require a second, adjunctive therapy to increase IOP lowering. Inotek believes an FDC of <I>trabodenoson</I> with
<I>latanoprost</I> has the potential to produce efficacy greater than either drug alone in a convenient one-drop, once daily treatment option for patients with glaucoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The issuance of the combination patent covering the use of <I>trabodenoson</I> with a prostaglandin analog is an important addition to Inotek&#146;s
growing intellectual property portfolio. This protects use of the combination of <I>trabodenoson</I> with any prostaglandin analog in a single, convenient daily eye drop,&#148; commented David P. Southwell, President and Chief Executive Officer of
Inotek. &#147;We look forward to reporting data from our recently initiated Phase 2 FDC trial of <I>trabodenoson</I> and the most commonly used prostaglandin, <I>latanoprost, </I>in the second half of 2017.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#146;530 patent broadly covers the use of <I>trabodenoson</I> and a prostaglandin analog as a combination, kit or method of use for reducing IOP.
Inotek&#146;s patent estate also includes composition of matter patents covering the <I>trabodenoson</I> compound through 2026 in the United States and through 2025 abroad, the crystalline formulation of <I>trabodenoson</I> used in
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eye drops through 2033 in the United States and patents relating to the use of <I>trabodenoson</I> for reducing IOP, which expire in 2031 in the United States, and, if issued abroad, will expire
in 2030. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inotek Pharmaceuticals Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inotek Pharmaceuticals&nbsp;is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma
and other eye diseases. The Company&#146;s lead product candidate in glaucoma,<I> trabodenoson</I>, is a first-in-class, selective adenosine mimetic currently in Phase 3 development.&nbsp;<I>Trabodenoson</I>&nbsp;was developed in Inotek&#146;s
laboratories and is designed to restore the eye&#146;s natural pressure control mechanism by targeting the adenosine A<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> subreceptor. Additionally, the Company is evaluating the potential for
selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit www.inotekpharma.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These forward-looking statements often include words such as &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;intend,&#148;
&#147;plan,&#148; &#147;estimate,&#148; &#147;seek,&#148; &#147;will,&#148; &#147;may&#148; or similar expressions. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date
made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source:&nbsp;Inotek Pharmaceuticals </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inotek Contact:
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Claudine Prowse, Ph.D., 781-552-4305 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President,
Strategy and Investor Relations Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cprowse@inotekpharma.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g231137g04d36.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g231137g04d36.gif
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M*1 Q.6-C8QA*6C&$I5J]YS%[G#%[I<;O]][O_\[O_YS>_\;O_[WO_P
M
M
M
M
M
M
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M5R" .PC@ C>!FQ($!@21@7F5*YZS$"8^2L*!="ED6NLN1 (N<$$(LNLI .1
M6P @ <4D@((0G""<+] 6#$+P*1F<X%,4",$'BD:!$XA 6Q0()[$ 8 $3Z("_
M>9OP!W(@D F88"!0LT %@A77Y0K&N9T!T'9^:QCP".:X#9D @$_<+ HD;@0L
MGD"T!A M"M#@;S4()P H8 -12> &Z.64!4 PD P#0,@"J8"P)A!.7Y58("$(
M@9)/+! 7=)>]ALW._F)5JYS_<*"V.,ZQ"TH0 E&%P 0A2 &&*Z L":1 !",0
M%09,\ (27$#!#/X =DM $ K$P 04UC#%/J!A3RF:(,22 <7(G#<@2T>W>NE
MAF##@0[812V&N0T'[9OC.@M+ B+(;@48?8()H^!OF[HUQ'P< @PPN@(HL$ *
M/'6">"F:4R(0%98!0.DK=YD$X&5V""Y@@G!R.LL.;7%K,H"84D? *$EQ0 ,:
M8Y@./ >Y#-$QW92LK,2!P%-4IK0$M!4"$<P; ",HL;96[., !VO+E Y5EK<L
M:0I8P (2* &G*,!H$V! 6'SV\J>7RP %-. M<LD*7" 0@0@D8*X*0'=#9/3V
MJ?#2+6_1YE3)4?[E)6O96@=7^04P</)HYTW@?SLY!BP0SGE']#<#$$  !C
M VC\Z <   *$GERP$N#H63% TW$;  %8_>I8O_I2I\[UKGO]ZV /N]C'3O:R
*F_WL:)]L0   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
